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1. Introduction 
Primary immunodeficiencies (PID) are genetic disorders of immunity whose incidence 
varies from 1:250 to 1:1,000,000 depending of disease and study population. Because of 
incomplete records of immunodeficiency in the world, is estimated that the prevalence of 
1:5,000 to 1:100,000 (Geha et al., 2007; Boyle & Buckley, 2007; Notarangelo,et al., 2010). Thus, 
the PID is a important group to public health as other genetic diseases that rely government 
support in a neonatal screening program such phenylketonuria (PKU) with incidence of 
1/15.000 (de Carvalho et al., 2007) and congenital hypothyroidism, with incidence of 1/4.000 
(American Academy of Pediatrics, 1993; Olivieri, 2009). The PID are classified in defective 
immune deficiency prevalent in predominantly antibody; combined immunodeficiencies, 
cellular immunodeficiencies, phagocyte defects, immune deficiencies associated with 
lymphoproliferative diseases, and deficiencies of complement system or secondary 
immunodeficiencies associated with other diseases. This classification is updated 
periodically by the International Union of Immunological Societies (IUIS), associated with 
the World Health Organization (WHO) (Geha et al., 2007; Notarangelo,et al., 2010). 
This classification is progressively adjusting to the rapid evolution of the field. Many new 
phenotypes (e.g. hemophagocytosis, thrombotic purpura, herpes encephalitis, Mendelian 
susceptibility to mycobacterial infection, epidermodysplasia verruciformis, chronic 
mucocutaneous candidiasis, autoinflammatory disorders, and anhidrotic ectodermal 
dysplasia with immunodeficiency) have emerged as reflecting new PID. 
Knowledge of PID is still deficient in many countries and within many countries, since 
doctors and health authorities are often poorly informed about their clinical presentations, 
diagnosis, importance and health impact of these diseases, and geographic factors that 
influence the release of same around the world (Sewell, 2006). Recent estimates of PID made 
by the European Parliament showed that approximately 1 in 800 to 10,000 people have PID 
that significantly affects your health, PID affect at least 10 million people worldwide, the 
true prevalence of PID in some forms of general population is estimated between 1 in 250 
and 1 in 500, data comparable with type I diabetes (1 in 700) and multiple sclerosis (1 in 
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1000), although more than 200 PID have been discovered, some are more common than 
leukemia and lymphoma in children (Banks, 2010). 
Initial efforts in classification of PID left WHO in 1970, where this first meeting was 
identified and classified 14 different entities, and in 2006, more than 100 types (Bonilla & 
Geha, 2006). Currently, they comprise more than 200 different types of genetic diseases that 
predispose the human host to recurrent infections, which may be associated with other 
disorders (Notarangelo et al., 2010), but also to chronic and systemic inflammation, 
hypersensitivity reactions, autoimmunity, and cancer. Advances in biological sciences and 
biotechnology are now making possible for the first time, to systematically assess the actual 
impact of PID in human health, and this promises to revolutionize the way we look at these 
diseases. 
Patients with PID have higher susceptibility to infection often accompanied by 
inflammatory disorders, hypersensitivity reactions, autoimmunity and cancer (Morimoto & 
Routes, 2008; Notarangelo 2010). The clinical presentation of patients is extremely broad, 
with asymptomatic individuals who have fulminating infection, which if not diagnosed and 
treated properly evolution to death (Chapel 2005; Bustamante et al., 2008a). Patients with 
PID have consequence of delay diagnosis and treatment permanent damage of body. This 
involves disabling from attending school and/or work, reducing the number of people with 
productive capacity, increasing the number of people hospitalized with high cost to 
government, increased mortality rate in children and adults of working age 
(Yarmohammadi et al., 2004; Bonilla et al., 2005). The delay in diagnosis leads to pulmonary 
complications such bronchiectasis and irreversible change in the quality of life of patients 
and their families (Kainulainen et al., 2001; Champi, 2002). 
Although this delay in diagnosis of PID is evident in countries or disadvantaged regions, 
also occurs in developed countries after multiple hospitalizations of patients. Thus, is 
recommended research and education in PID, since the prognosis of many patients can be 
improved by early diagnosis and appropriate access to care and treatment (Bonilla et al., 
2005; Turvey & Bonilla, 2009). In medical terms, there are three important reasons for 
understanding the PID, first, a high index of suspicion and early diagnosis may lead to 
treatments that save lives or bring significant improvement in quality of life, secondly the 
discovery of genetic defects in immunity makes possible family counseling and prenatal 
diagnosis, and thirdly, the study of the pathophysiology of genetic and immunological 
defects provides important tools to understanding the regulation of the human immune 
system (Bustamante et al., 2008b; Casanova et al., 2008; Lee & Lau, 2009; Fried & Bonilla, 
2009). In recent decades, no other field of immunology had so much progress in 
understanding how pathophysiology of primary immunodeficiencies. These developments 
have resulted not only in understanding of immunodeficiencies, but understanding of 
immune system in humans (Boufisha et al., 2010). Patients with PID are considered not 
successful experiments of nature that brought many benefits to medicine in the installation 
of diagnostic protocols and rational treatment, location of targets for gene therapy and 
assessment of need for bone marrow transplantation and its benefits (Griffith et al., 2009; 
Neven et al., 2009; Pessach et al., 2009; Kohn 2010). This knowledge was translated  
into association of specific defects of immunity with signs and symptoms that can establish 
correct diagnosis of disease, beyond the description of new immunodeficiency (Cassimos  
et al., 2010). Since the PID diseases are congenital and hereditary character, children are  
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overweight patients, however, a greater number of adults have been diagnosed as children 
grow and become adults (Bustamante et al., 2008a). How healthy children have on average 
6-8 mild respiratory infections, especially upper airway in first year of life and more than six 
episodes of otitis and gastroenteritis per year in the first three years of life, young children 
with high environmental exposure or with siblings who attend schools may exceed these 
averages by one to two years, the diagnosis of PID is often underestimated (Puck, 1997). But 
they may be observed in children with normal development, which may harbor latent PID 
or low impact on the immune system. Pediatrics specialize in PID ensure that half children 
are taken by parents to the doctor with a history of recurrent infections are normal, and 
other 50%, 30% have allergies, 10% other diseases and 10% PID (Grumach et al., 1997). To 
aid diagnosis and reporting of PID, the American Red Cross and Jeffrey Model Foundation 
developed the 10 warning signs suspected for PID. For experts (Modell, 2007a; Modell, 
2007b), these signs are considered extremely important, since the prognosis and therapeutic 
success depends upon prompt diagnosis, and most are performed in referral centers. 
However, some authors consider the 10 warning signs not sensitive or specific, since a third 
of patients do not present single warning sign (Aloi et al., 2007). Once diagnosed with PID, 
the patient is referred to clinical immunologist who directs specific treatment, 
immunizations, and definitive and specific diagnosis. Thus, there is a gain in quality life of 
patients and their families, avoiding sequels, unnecessary suffering and high social cost.  
The therapeutic treatment these patients involve three basic tenets: reduce the exposure  
to the infectious agent, effective or prophylactic antimicrobial therapy, replacement of  
deficient immune functions (Garcia et al., 2007). During the evaluation of PID is essential 
documentation of the patient's clinical history, frequency, duration and complications of 
infections, outbreaks of infection, microorganisms involved and response to treatment, and 
anatomical defects, allergic processes and metabolic disorders (Bonilla et al., 2005). A 
detailed family history should be taken into consideration, since many PID are linked with X 
chromosome and the presence of children in maternal family with recurrent infections, or 
death in childhood due to severe infection indicates the possibility of PID. Initially, 
screening tests are indicated or initial and advanced testing as suspected PID (Sewell et al., 
2006). In general, immune assessment requires specialized laboratory and high financial cost, 
and it comes to pediatric patients, should be chosen methods that can be executed with low 
amount of blood (Oliveira & Fleisher, 2010). The diagnosis of some PID may be removed if 
they are used and selected screening tests such blood test for congenital neutropenia, 
leukocyte adhesion deficiency (LAD), severe combined immunodeficiency (SCID) and 
Wiskott-Aldrich Syndrome (WAS), or immunoglobulin’s quantification in suspected 
predominantly antibody defects (Gill, 2002). The diagnostic criteria are divided into three 
categories, definite, probable and possible. In ensuring inclusion of patients with 
polymorphic variants in genes associated with PID and specific clinical and laboratory 
changes, the patient must meet all criteria characteristic of the disease (Conley et al., 1999). 
The delay in diagnosis is often associated with limited access to specialized resources 
(Lindegren, 2004), is not unique to developing countries (Liang et al., 2008), leading to large 
variation between numbers of cases (Stihem, 2004). In Finland, the common variable 
immunodeficiency (CVID) showed delay time diagnosis of 5 years in 2/3 of patients and 10 
years in 1/3 these (Kainulainen et al., 2001), in United Kingdom this delay was 6.2 years 
during 1989 to 1995, and decreased 3.5 years after implantation of government program to 
guide distribution of national guidance on recognition and diagnosis of PID, after a study  
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conducted between 1996 to 2002 (Seymour et al., 2005). To be assured diagnostic quality 
indicators should be generated which include patient registration data, which together form 
the field and field set and its variables called record. These cases are based registry designed 
to improve patient care, but are useful for studying diseases. An example is early records of 
368 patients with chronic granulomatous disease (GCD) by American Foundation for 
Immunodeficiencies started in 1993, allowing a calculation of incidence of the disease for 
USA born in 1/200.000 (Winkelstein et al., 2000). In 1997, this study has been expanded to 
Common Variable Immunodeficiency (CVID), Wiskott-Aldrich Syndrome (WAS), Severe 
Combined Immunodeficiency (SCID), Leukocyte Adhesion Deficiency (LAD), DiGeorge 
Syndrome, Hyper-IgM Syndrome (HIGM) (Winkelstein et al., 2003) and X-Linked 
Agammaglobulinemia (XLA) (Winkelstein et al., 2006), showing concern in development 
systems of records, population data for estimating incidence, prevalence and characteristics 
of disease. These data are important to maintain epidemiological studies and research and 
design of new clinical trials, reducing mortality, increasing survival and improved quality of 
life. In Europe, this service is performed by European Society for Immunodeficiency-ESID 
non-governmental organization that aims, to facilitate exchange of information between 
doctors, nurses, researchers, patients and their families, promote research into causes, 
mechanisms and treatment of PID (Sewel et al., 2006; de Vries, 2006; Guzman et al., 2007; 
Gathmann et al., 2009). This group was established in 1993, Society in 1994, and receives data 
from 66 specialized centers in 26 European countries. In 2005 record showed amount of 
10,000 patients from 26 countries with prevalence of 4-47/1.000.000, and the European 
internet-based patient and research database for primary immunodeficiencies results in 
7,047 patients with PID in 30 countries (Knerr et al.,2008) and 7430 patients from 39 countries 
have been documented in the ESID database (Gathmann et al., 2009). 
In Latin America in 1993, was created the Latin American Group for Immunodeficiencies 
(LAGID) to study the prevalence of PID in different regions of Latin America and promote 
awareness of these diseases. There are also databases online with identification of mutations 
locus in specific cases of PID that are established by ESID and extended by others 
researchers. This was initiated in 1995 to collect data in Bruton's tyrosine kinase mutations 
(BTK) in XLA (Lindegren et al., 2004). This occurred in Brazil, through the creation of 
Brazilian Group of Primary Immunodeficiencies (BRAGID), which through information 
campaigns, increased the number of 314 cases in 2000 to 536 cases in 2004 with Southeast 
region responsible for 70% total cases. Another relevant factor in understanding the 
epidemiology of PID is introduction of specialized care networks. In England there is the 
National Specialist Advisory Group Comissionary (NSCAG) of National Health System 
(NHS), which tracks PID complex cases, such the Great Ormond Street Hospital (Jones & 
Gaspar, 2000) and Newcastle General Hospital (Slatter & Gennery, 2010).  
Several international initiatives are currently underway to promote awareness PID and 
increase number of diagnosis and registration of PID (http://www.primaryimmune.org/ 
resources/resources.htm) (Modell, 2007a; Modell, 2007b; Pickett et al., 2008). Considering 
the increasingly frequent recognition of these diseases and their valuable contribution to 
understanding human immune system and mechanisms of defense against infections (more 
frequent medical care in worldwide) (Alcais et al., 2009), it is essential establish the 
frequency and type in population (Casanova & Abel, 2007; Ballow et al., 2009). The lack of 
proper diagnosis and treatment are the main problems in patients with PID in Latin 
America. These are related to lack of proper training of pediatrics, leading to misdiagnosis 
or late diagnosis, lack of proper screening, lack of government resources to implementation 
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of diagnostic centers and disinterest of private institutions in diagnosis of PID, regional 
variability access to educational program and establishment of diagnostic and treatment 
center (Pickett et al., 2008; Condino-Neto et al., 2011; Leiva et al., 2011). 
2. Difficulties in diagnosis, treatment and education of PID in Latin America 
2.1 Argentina 
The main diagnostic centers in Argentina are located in Buenos Aires, and other centers are 
located in La Plata, Rosario, Cordoba and Mendoza. These centers are accessible and 
without cost to the community, provided that patients are referred by doctor. Private 
hospitals in Argentina offer only partial diagnosis, because no they have laboratories and 
professionals specialized in PID. Patients in Paraguay, Bolivia and Uruguay are also 
diagnosed and treated in Buenos Aires since these countries do not have adequate support. 
As their countries do not encourage their costs, or they do not have health insurance, this 
burden financially immunology centers in Argentina (Maceira et al., 2010). Patients with PID 
who need IVIG are usually met in Buenos Aires, and treatment is not automatically 
continued in the pediatric patient who came into adults, it should be transferred from 
pediatric hospital to hospital for adults, interrupting treatment (Krasovec et al., 2007). In 
Argentina, immunologists are not recognized experts by the Ministry of Health, and only 
two hospitals in Buenos Aires offer scholarships programs and post-graduate training  
in immunology funded by government agencies (Galicchio et al., 2010; Condino-Neto  
et al., 2011). 
2.2 Brasil 
It is estimated that Brazil has 2,000 patients on treatment and approximately 20,000 patients 
with PID (Leiva et al., 2007). Immunological diagnosis is supported by numerous centers 
located in São Paulo, Minas Gerais, Paraná, Rio Grande do Sul, Bahia and Rio de Janeiro 
(Grumach et al., 1997; Leiva et al., 2007). Centers located in southeast of country have 
specialized researchers, structure and molecular diagnostics. In Brazil, the federal government 
assists the movement of patients from regions without infrastructure to specialized centers, 
and coverage for certain screening tests of PID (Ocké-Reis & Marmor, 2010; Paim et al., 2011). 
High costs and access to specialized laboratories are considered major problems by doctors for 
the diagnosis of PID (results available http://www.bragid.org.br/download/graphicos.pps), 
with strong educational, whose website presents PID centers throughout Brazil, journals, 
reviews and articles, case discussions, and announcements of meetings. This is supported by 
St. Jude's Hospital children and government agencies FAPESP and CNPq. Activities of this 
group include completion of first and second Summer School of PID by LAGID, 
implementation of Electronic Registration of Latin America Immunodeficiencies 
(http://imuno.unicamp.br:8080/) with installation of hardware in UNICAMP center 
computing support of ESID. The Federal University of São Paulo-UNIFESP, in partnership 
with Jeffrey Modell Foundation and Baxter International, created the first Jeffrey Modell 
Diagnostic Center for PID in Latin America; with goal of enabling physicians perform 
diagnostic, treatment and education of patients and PID cases reported in Brazil and Latin 
America. Patients with PID who need IVIG in Brazil receive government financial support, 
and not institutions or private health insurance, where patients should be initially admitted for 
diagnostic and treatment center. In Brazil, there are numerous funding agencies to residency 
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programs in allergy and immunology, although only few centers are able to train professionals 
and PID treatment, located in São Paulo (Costa-Carvalho et al., 2011; Condino-Neto et al., 2011). 
2.3 Chile 
The best laboratories for diagnosis of PID in Chile are located in Santiago, Temuco, 
Valparaiso and Concepcion. Initial screening tests for PID can be performed in large 
hospitals, although it does not receive government financial support (Goic & Armas, 2010). 
As in most underdeveloped countries in Latin America, the diagnosis of PID is often 
performed after numerous episodes of infection and treatment, and patient referral to 
specialist in infectious diseases, and finally to immunology center. Patients with PID, who 
need IVIG, are not reimbursed by the public health system for PID, burdening the costs to 
patients, which makes the treatment is not performed or interrupted. Chile has a three-year 
residency in immunology at the University of Santiago of Chile, providing training care of 
adult and pediatric patients (Condino-Neto et al., 2011). 
2.4 Colombia 
Colombia has a national PID referral center located in University of Antioquia in Medellin, 
which has laboratory equipped to perform molecular and immunological diagnosis of PID, 
and other centers and programs are being developed in Bogota, Cali, Cartagena and 
Barranquila. Currently, 80% of cases of PID in Colombia come from Antioquia (Montoya et 
al., 2002; Obando et al., 2005) and neighboring states, which represents less than 20% of 
Colombia population. Most clinical laboratories in Colombia are able to perform initial PID 
screening, but specific tests are only available in Medellin and Bogota (Montoya et al., 2002; 
Diaz et al., 2008). In Colombia, the government Compulsory Health Plan (POS) provides 
basic coverage for PID and additional coverage can be obtained from private insurance 
companies (Gonzáles et al., 1999; Cardona & Segura, 2011). Patients with PID, who need 
IVIG, are not refunded by POS, but IVIG treatments are covered by private insurance 
companies, who refunded through government's national fund FOSYGA. In this country 
there is Foundation for Diana Garcia de Olarte PID, which supports and develops 
educational programs, provides infrastructure for IVIG treatment centers and offers legal 
advice for patients who need IVIG (Montoya & Sorensen, 2001). The University of Antioquia 
in Medellin has immunology program for medical residents, and like Latin American 
countries, this prefer specialize in other areas, since the financial return is greater (Condino-
Neto et al., 2011). 
2.5 Honduras 
Honduras has two PID diagnostic centers, located in Tegucigalpa and San Pedro Sula, 
accessible to entire community, first laboratory support specific PID, and country have 
serious problems in laboratory diagnosis and access costs (Leon, 2003), availability of IVIG 
and cost. Only two hospitals in Tecigalpa, including National Institute of Social Security, 
provide treatment with IVIG. The country has no specific PID program residency, and 
receives training only three months on basic immunology, autoimmunity, allergy and 
immunodeficiency (Condino-Neto et al., 2011). 
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2.6 Mexico 
Mexico has specialized centers diagnosis of PID in Mexico City, Monterrey and Guadalajara, 
and molecular diagnosis of some PID can be performed only in Mexico City. Mexico has 
serious access problems to laboratory tests, cost and medical education in PID (Romero-
Márquez & Romero-Zepeda, 2010; Yavich et al., 2010). The Access to IVIG is extended to 
public health system and is administered in public hospitals and clinics, but doctors do not 
follow specific guidelines for the administration of IVIG. The use of IVIG represents 20% of 
coast in obtaining drugs by National Institute of Pediatrics in Mexico City. In Mexico, there 
are plenty residency programs in allergy and immunology, with emphasis on allergies. Only 
the National Institute of Pediatrics in Mexico City has residency program with emphasis on 
pediatric allergy and immunology (Condino-Neto et al., 2011). 
3. Latin American group of immunodeficiency 
One of major problems of records diseases in underdeveloped countries has been limitation 
of diagnostic and treatment, and send reports of cases by physicians, resulting in 
overestimation in certain clinical centers in collection of samples, since most of these centers 
is reference to some types of PID, and lack of standardized definitions of cases makes it 
impossible to calculate rates of healthy population from this source, by only reporting 
positive cases without reference population data (Condino-Neto et al., 2011). 
The PID diagnosis is performed in immunology centers, usually located in major cities of 
Latin American countries, and the vast majority of pediatricians and general practitioners 
are not prepared to establish PID diagnosis. The medical community educator has a role in 
awareness of population and health professionals in PID. In 1997, the University of São 
Paulo, Brazil, 166 cases of PID were registered with frequency of predominantly humoral 
defects (60.8%), T cell defects (4.9%), combined T-and B-cell deficiencies (9, 6%), phagocyte 
disorders (18.7%) and complement deficiency (6%). During observed period, 13.8% of 
children died, primarily of recurrent infections. In comparison with other reports, was 
higher relative frequency of phagocyte and complement deficiency. This is the first report 
on PID over 15 year’s observation (1981-1996) (Grumach et al., 1997). In 1998, a Colombia 
study with 83 PID patients demonstrated most common disturbance was antibody 
deficiency (74,6%), followed abnormalities of unspecific mechanisms (13,3%), deficiencies of 
cell mediated immunity (9,6%), and mortality ratio was 6% especially in patients with 
cellular deficiency (Núñes, 1988). 
In Antioquia, Colombia, between August of 1994 and July of 2002, 98 patients was 
registered with diagnosis of PID, with most frequent report antibodies deficiency (40,8%), 
followed by combined deficiencies (21,4%)(Montoya et al., 2002). In Latin America, in 
1993, immunologists from four Latin American countries (Argentina, Brazil, Chile, 
Colombia), created the Latin American Group for Immunodeficiencies (LAGID) to study 
the frequency of PID and promote knowledge by general practitioners and specialists in 
allergy and immunology, including Latin American countries, creating a record in each 
participating country. Currently, 14 countries belong to this group, which had record 3321 
patients in 2004.  
LAGID was implemented in 1993 with the mission to include several Latin American 
countries, spread the educational and awareness programs, establish PIDD registries, and 
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promote annual scientific meetings with the participation of well-recognized international 
authorities in the PID field, This environment made possible the intensive interaction among 
Latin American doctors which in turn interacted with North American and European 
investigators resulting in a network, significant scientific development in Latin America, 
and the several resultant publications, starting with the clinical studies based on the LAGID 
registries 
In order to encourage the registration of cases by LAGID, this sets out on its website 
(http://www.lagid.lsuhsc.edu) the objectives: 
1. Knowing the frequency of different PID 
2. Compare the frequency of different PID by region and country 
3. Knowing the time that elapses between the onset of symptoms and diagnosis and 
measure whether this time can be shortened through the dissemination of knowledge 
about PID 
4. Create awareness in importance of PID in primary care physicians, educators from 
basic and clinical science and health authorities to decide how to allocate resources for 
diagnosis and treatment of diseases in diverse groups 
5. Promote research in various aspects of specific PID that would not be possible to settle 
in very small groups of patients 
6. Disseminate the findings in field of Latin American PID to medical and international 
immune community 
7. Facilitate the formation of support groups for parents and sponsors 
The first LAGID published a series of studies in 1998, recording instances of medical 
services totaling 1428 patients of eight countries (Argentina, Brazil, Chile, Colombia, 
Costa Rica, Mexico, Paraguay, Uruguay), concluding that predominantly antibody 
deficiencies were reported in 58% patients, followed by cellular and antibody 
immunodeficiencies associated with others abnormalities in 18%, immunodeficiency 
syndromes associated with granulocyte dysfunction in 8%, phagocytic disorders in 9%, 
combined cellular and antibody immunodeficiencies in 5%, and complement deficiencies 
in 2% of patients (Zelazko et al., 1998). 
In a second step, this same group published a second series of studies in 2007, documenting 
3.321 cases of 12 Latin American countries (Argentina, Bolivia, Brazil, Chile, Colombia, 
Costa Rica, Ecuador, Mexico, Peru, Paraguay, Uruguay and Venezuela). The most common 
form of PID was predominantly antibody deficiency (53,2%), other well-defined PID 
syndromes such ataxia telangiectasia, Hyper IgE and Di George (22,6%), Combined T- and 
B-cell Immunodeficiency (9,5%), phagocytic disorders (8,6%), diseases of immune 
dysregulation (3,3%) and complement deficiencies (2,8%). All countries that participated in 
the first publication in 1998 reported increase in PID register cases, ranging between 10 and 
80% (Leiva et al., 2007). 
In second LAGID record, Argentina recorded 852 cases of predominantly antibody 
deficiency, and Brazil 404 with predominates isothype deficiencies of light chain with 
normal numbers of B cells. Brazil reported 75 cases of Combined T-and B-cell 
Immunodeficiency and Argentina 69 cases. Like other well-defined syndromes, Argentina 
reported 60 cases of Di George Syndrome, 42 of Hyper IgE Syndrome and 40 of Wiskott-
Aldrech Syndrome, Costa Rica 82 cases of DNA repair defects and Brazil 37 cases of Chronic 
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Mucocutaneous Candidiasis. Representing diseases of immune dysregulation, Argentina 
reported 22 cases of Immunodeficiency with Hypopigmentation, followed by 14 cases of 
Brazil. Congenital defects of phagocytic number, function or both, Brazil reported 50 cases 
of cyclic neutropenia and 42 cases of Chronic Granulomatous Disease (CGD), and 
Argentina 46 cases. Brazil reported 50 cases of deficiency complement, followed by 13 
reports of Argentina (Leiva et al., 2007). Like others studies, predominantly antibody 
deficiency was the principal PID observed in Latin America, Australia (Baumgart et al., 
1997; Kirkpatrick et al., 2007), China (Zhao et al., 2006; Wang et al., 2011), Egypt (Reda et 
al., 2009), French (CEREDIH, 2010), Hong Kong (Lam et al., 2005), Iran (Aghamohammadi 
et al., 2002; Farhoudi et al., 2005; Rezaei et al., 2006), Italy (Luzi et al., 1983), Kuwait (Al-
Herz, 2008), Netherland (Zegers et al., 1994), Norway (Stray-Pedersen et al., 2000), Poland 
(Bernatowska et al., 1998), Republic of Ireland (Abuzakouk et al., 2005), Spain (Matamoros 
et al., 1997; Milá et al., 2001), Swiss (Ryser et al., 1998), Taiwan (Lee et al., 2011), Thailand 
(Benjasupattananan et al., 2009), Tunisia (Bejaoui et al., 1997) and USA (Javier et al., 2000; 
Stiehm, 2007), Studies in other countries reveled major number of granulocyte 
dysfunction in India (Verma et al., 2008), and Combined T-and B-cell Immunodeficiency 
in Turk (Shabestari et al., 2007). 
On October 14, 2009, a group of experts from six Latin American countries (Argentina, Brazil, 
Chile, Colombia, Honduras and Mexico) and representatives of LASID meet in Cartagena de 
Indias in Colombia to discuss particular needs of each country about PID. Also this year, was 
created on-line Program Registration in Latin America (Registration of Society for 
Immunodeficiencies Latin American-LASID) in site http://deficiencia.unicamp.br:8080/, to 
provide information of PID epidemiology in Latin America. This meeting was held on 28 and 
29 April in São Paulo, with the participation of 90 participants from Argentina, Brazil, Chile, 
Colombia, Honduras and Mexico, three faculty members from the USA and a faculty member 
of ESID. The online registration for Latin America was adapted from the record set ESID in 
Europe; Latin America is supported by Jeffrey Modell Foundation and National Council for 
Scientific and Technological Development (CNPq) of Brazil. From this date, 24 centers were 
enrolled in diagnosis, treatment and research, with more than 600 registered patients. In others 
countries, the online database network make good results in records of PID (Eades-Perner et 
al., 2007; Guzman et al.,; 2007; Gathmann et al., 2009), 
The LAGID has published four reports and proceedings; the first two papers focused on the 
prevalence and characteristics of PID patients in Latin America (Zelazco et al., 1998; Leiva et 
al., 2007); the third and fourth summarized deficiencies in PID diagnosis and treatment in 
Latin America and described features of educational outreach program, immunology 
fellowship program, and laboratory network aimed at correcting these deficiencies 
(Condino-Neto et al., 2011; Leiva et al., 2011). From July 2009 to September 2010, the LAGID 
recorded 838 cases of PID. 
In April 2011, the registry of Immunodeficiencies completed two years, with more than 1000 
cases reported from 35 centers representing various Latin America countries. Recently, the 
Committee decided to hold LASID collaborative studies with the recorded data to better 
understand profile of prevalent PID, such XLA, HIgM, and CGD, filling out form and 
sending data to protocololasidxla@bragid.org.br or protocololasidhim@bragid.org.br or 
protocololasiddgc@bragid.org.br depending on PID. The group also offers financial 
education programs in PID, with projects submitted to e-mail info@imunopediatria.org.br. 
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Those studies contributed with new insights on clinical presentation and impacted 
positively on the molecular diagnosis of PID. All together the Latin American experience 
shows that BCG complications is prevalent among SCID, T-cell deficiencies, and CGD 
patients; that fungal infections is highly prevalent among X-linked HIGM patients, and that 
ataxia-teleangiectasia is especially frequent in Mexico and Costa Rica. Currently Chile is 
building a new diagnostic center at University La Frontera that will interact with research 
centers in Argentina, Brazil, and Colombia. This strategy will strength even more the 
interaction among the several Latin American research centers. 
Studies by LAGID showed numerous factors responsible for delay in diagnosis and treatment 
of patients with PID. Most pediatricians and family physicians in Latin America are not 
sufficiently trained to carry out the diagnosis of PID, there is a low amount of specialized 
installations for specific immunological tests, there is limited coverage for screening tests given 
by the government or private institutions, regional variability access to health and failure to 
comply with guidelines in certain countries and regions. To improve some of these aspects, 
diagnosis and treatment of patients with PID, experts from Latin America and the USA meet 
to discuss three specific programs, educational program (The L-Project), scholarships program 
and establishing of laboratory network to expand access to data (The Latin América Advisory 
Board on Primary Immunodeficiencies) (Leiva et al., 2011; Condino-Neto et al., 2011). 
3.1 Educational program 
The educational program (L-Project) was established to create increased awareness of 
general public, continuing education network on PID, promote basic and clinical research of 
PID and inform government officials in impact of PID on health published in Latin America. 
This program covers students, residents, pediatricians, nurses and officials involved in 
health system. It also emphasizes encouragement medical students seeking academic 
placement of teaching, research and clinical PID. These programs include summer school, 
containing cases and report on short-term programs associated with PID infection, 
dissemination of information by radio, television, websites, newspapers, magazines and 
educational material for community (Marodi & Casanova, 2009; Leiva et al., 2011). This 
proposal directly contributes to knowledge generation and increase technological capacity 
of Latin America in this field. It is virtuous chain where all the researchers and the 
community involved propagate their knowledge acquired in other centers of reference, 
allowed expansion of existing lines of research in Brazil. 
3.2 Summer school 
Creating of Summer school is considered a viable solution to promote scientific interaction, 
and standardization of PID knowledge in different member countries because educational 
systems and medical residents differ in each country member (Condino-Neto et al., 2011; 
Leiva et al., 2011). In Brazil, São Paulo in 2006 was held the first Summer School, based on 
model proposed by ESID and CIS. This meeting was attended by 12 teachers of LAGID, 
ESID and CIS experts PID and 12 students, where they were focused biochemical and 
molecular diagnosis PID, major PID in Latin America; IVIG therapy guidelines, 
hematopoietic bone marrow transplantation; communication network LAGID. New meeting 
was held in 2008 in Temuco, Chile, and recently in 2010, Bahia, Brazil, with inclusion of 90 
students from different Latin America countries. 
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3.3 Scholarship program offer 
One of great difficulties encountered in developing countries for training professionals in 
PID is to awaken academic and professional interests, without compromising quality of life 
and survival of students and health professionals. Thus, different Latin American countries 
offer scholarships funded by educational institutions and other entities, governmental or 
private, with development of people involved and trained in specific areas of health. One of 
major problems seen in developing countries is the absence of jobs, which means that many 
students, just looking for graduate services that offer post-graduate scholarships, forgetting 
commitment they have with the community. Another problem in Latin America is 
formation of highly trained and qualified for certain areas of education and research, which 
are not absorbed by countries, end migrating to other parts of world. To resolve these 
problems, the Advisory Council LAGID determined availability of scholarships for doctors 
interested in area of clinical PID, as well doctors and teachers interested in immunology. 
The participating institutions were willing to participate in record LAGID, and grant 
applicants to submit personal statement, career development plan, and mentor involved 
with project statement of no conflict of financial interest and letters of recommendation. In 
this agreement, it was established that no country could be assigned more than two grants 
during period of two years, and beneficiaries of scholarship must publish report on its 
activities or clinical results or research (Leiva et al., 2011). 
3.4 Creation of centers of education, diagnosis and treatment 
One of the major problems encountered in developing countries is lack of proper training of 
physicians and pediatric regional variability in access to educational program and 
establishment of diagnostic and treatment center. Thus, education and training are needed 
for specialists, pediatricians, general practitioners from different countries and regions of 
Latin America, ensuring that they are able to recognize warning PID signs. This includes 
creation of Summer School, symposia and conferences of PID. These educational efforts 
should also be understood to medical students, nurses and general public. For that, 
programs are needed government and private funding, and network (Leiva et al., 2011). In 
Brazil, the Jeffrey Modell Foundation, and Baxter pharmaceutical industry, created on April 
29, 2009 at Federal University of São Paulo-UNIFESP, the first Jeffrey Modell Diagnostic 
Center for PID in Latin America, based in field of Immunology pediatric UNIFESP, with 
working points in different parts of the country. The Jeffrey Modell Diagnostic Center 
operates in front of medical education, diagnosis and records of PID and patient education 
(Modell, 2007a; Modell, 2007b). Other diagnostic centers sponsored by the Jeffrey Modell 
will be opened in Mexico, Argentina, Colombia and Chile. Advancing educational model for 
educational outreach in Latin America is observed in the Brazilian Group of Human 
Immunodeficiency (BRAGID) (http://www.bragid.org.br), whose number of registered 
doctors increased from 190 in 2002 to 2.500 in 2009, after creation of local seminars on dating 
PID. The BRAGID provides information on warning PID, different clinical presentation PID 
of and diagnostic laboratories. Offer clinical cases that can be discussed in Internet. This 
model is followed in Colombia, which has specialized site that shows warning PID signs, 
types of PID and use of IVIG. In other Latin American countries, government agencies 
related to areas of health are more concerned with control of infectious diseases, and most 
professionals in the field of immunology work independently. 
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4. Conclusion 
The PID are congenital and inherited diseases that affect the immune system, which 
occurrence in population varies by type of study and study group. Recent studies indicate 
that these values in the general population are underestimated and are one of the biggest 
problems and lack of knowledge, both worldwide and Latin America. Many factors 
compromise its knowledge, such as lack of education centers, professional structure, and 
laboratory records. The incidence of PID in Latin America is similar to that observed in 
different parts of the world, with predominantly antibody defects. In Latin America, adds to 
these, the lack of government support and private initiative. To redress this problem was 
created LAGID, which hosts Latin American countries concerned with knowledge of 
incidence, diagnosis, treatment and discovery of new PID. For this, congresses are held, 
online records and establishing laboratory training, diagnosis and treatment of PID, based 
on the model established in Europe. 
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